Kairos Pharma Ltd Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
-22.8%projected annual EPS growth
Analyst Coverage
2analysts covering
FY EPS (est.)
-$0.37next fiscal year
Monitoring Framework
Key Performance Indicators
Cash and Cash Equivalents Quarterly3.7MTarget: Sufficient liquidity to fund operations and clinical trials
Quarterly Net Loss Quarterly-1.7MTarget: Stabilization of operating expenses
Research and Development (R&D) Expense Quarterly684KTarget: Efficient allocation of capital to clinical trials
Watch Items
- Going Concern Risk and Cash RunwayTrigger: Cash runway falling below 6 months based on current quarterly burn rateAction: Accelerate ATM offerings, secure strategic partnerships, or utilize non-dilutive clinical funding
- ENV-105 Phase 2 Prostate Cancer Trial MilestonesTrigger: Delay in announcing key safety and efficacy results beyond Q3 2026Action: Review clinical trial site execution and optimize patient enrollment strategies
- CL-741 Phase 1 Clinical Trial InitiationTrigger: Failure to initiate first-in-human clinical trials for CL-741 in 2026Action: Expedite pre-IND studies and leverage clinical consortia at Cedars-Sinai Medical Center
Research as of 20 Jun 2026